A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women

被引:109
作者
McCarthy, JM
Richard, G
Huck, W
Tucker, RM
Tosiello, RL
Shan, M
Heyd, A
Echols, RM
机构
[1] Hill Top Res, Fresno, CA 93710 USA
[2] Univ Florida, Coll Med, Div Pediat, Gainesville, FL 32611 USA
[3] Adv Clin Res, Salt Lake City, UT 84101 USA
[4] Wenatchee Valley Clin, Wenatchee, WA 98801 USA
[5] Bayer Corp, Pharmaceut Div, W Haven, CT 06516 USA
关键词
D O I
10.1016/S0002-9343(99)00026-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE: Bladder infections are very common in otherwise healthy women, and short-course antimicrobial treatment appears effective for many episodes of cystitis. This study reports the results of short-course ciprofloxacin, ofloxacin, and trimethoprim/sulfamelhoxazole therapy. PATIENTS AND METHODS: We performed a randomized, double-blind study of the efficacy and safety of a 3-day course of oral ciprofloxacin 100 mg twice daily, ofloxacin 200 mg twice daily, or trimethoprim/sulfamethoxazole 160/800 mg twice daily in women with acute, uncomplicated, symptomatic lower urinary tract infection. RESULTS: A total of 866 patients were enrolled, of whom 688 (79%) were evaluated for the efficacy of treatment (229 treated with ciprofloxacin, 228 treated with trimethoprim/suliamethoxazole, and 231 treated with ofloxacin). The most frequent reason for exclusion was the failure to identify a pretreatment pathogen. The most commonly isolated pathogen was Escherichia coli (81%). Eradication of the pretreatment pathogen at the end of therapy occurred in 94% of ciprofloxacin, 93% of trimethoprim/sulfamethoxazole, and 97% of ofloxacin-treated patients. At follow-up evaluation at 4 to 6 weeks, recurrence rates (relapse or reinfection) were 11% in the ciprofloxacin, 16% in the trimethsprim/sulfamethoxazole, and 13% in the ofloxacin treatment group. Clinical success at the end of therapy was 93% in the ciprofloxacin, 95% in the trimethoprim/sulfamethoxazole, and 96% in the ofloxacin treatment groups. The frequency of all adverse events was 31% for ciprofloxacin, 41% for trimethoprim/sulfamethoxazole, and 39% for ofloxacin-treated patients (P = 0.03). Premature discontinuation of study drug due to an adverse event was more common in trimethoprim/sulfamethoxazole-treated patients (n = 9) compared with those given ciprofloxacin (n = 2) or ofloxacin (n = 1; P = 0.02). CONCLUSION: Ciprofloxacin, ofloxacin, and trimethoprim/sulfamethoxazole had similar efficacy when given for 3 days to treat acute, symptomatic, uncomplicated lower urinary tract infection in women. (C) 1999 by Excerpta Medica, Inc.
引用
收藏
页码:292 / 299
页数:8
相关论文
共 20 条
[1]   TOLERABILITY OF FLUOROQUINOLONE ANTIBIOTICS - PAST, PRESENT AND FUTURE [J].
BALL, P ;
TILLOTSON, G .
DRUG SAFETY, 1995, 13 (06) :343-358
[3]  
Boscia J A, 1987, Infect Dis Clin North Am, V1, P893
[4]  
CRAFT JC, 1991, EUR J CLIN MICROBIOL, P195
[5]  
FINEGOLD SM, 1965, PROGR PYELONEPHRITIS, P159
[6]  
HOOTON TM, 1995, JAMA-J AM MED ASSOC, V273, P41
[7]   SINGLE-DOSE AND 3-DAY REGIMENS OF OFLOXACIN VERSUS TRIMETHOPRIM-SULFAMETHOXAZOLE FOR ACUTE CYSTITIS IN WOMEN [J].
HOOTON, TM ;
JOHNSON, C ;
WINTER, C ;
KUWAMURA, L ;
ROGERS, ME ;
ROBERTS, PL ;
STAMM, WE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (07) :1479-1483
[8]   OFLOXACIN VERSUS TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF ACUTE CYSTITIS [J].
HOOTON, TM ;
LATHAM, RH ;
WONG, ES ;
JOHNSON, C ;
ROBERTS, PL ;
STAMM, WE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (08) :1308-1312
[9]   ADVANCES IN THE UNDERSTANDING AND TREATMENT OF URINARY-TRACT INFECTIONS IN YOUNG-WOMEN [J].
IRAVANI, A .
UROLOGY, 1991, 37 (06) :503-511
[10]   TREATMENT OF UNCOMPLICATED URINARY-TRACT INFECTIONS WITH TEMAFLOXACIN [J].
IRAVANI, A .
AMERICAN JOURNAL OF MEDICINE, 1991, 91 :S124-S128